Pharmacologic treatments for covid-19 patients
Itolizumab vs Standard care
Hospitalized patients
Forest plots
(last update: 2021-04-08)
To access all information :
- click here for Hospitalized patients
You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.
Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=167
Back to your research
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| CTRI/2020/05/024959 Kumar S, Exp Opin Biol Ther, 2021 Full text Commentary Commentary |
Private |
Itolizumab |
Standard care |
RCT | Patients with confirmed COVID-19 (severe) admitted to 4 centers in India | N=32 |
Some concerns Details |
|